JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mezaki, T.
Right arrow Articles by Kimura, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mezaki, T.
Right arrow Articles by Kimura, J.

Journal of Neurology, Neurosurgery, and Psychiatry, 1994, Vol 57, 1535-1537

PAPERS

Optimisation of botulinum treatment for cervical and axial dystonias: experience with a Japanese type A toxin

T Mezaki, R Kaji, T Hamano, T Nagamine, H Shibasaki, T Shimizu and J Kimura
Department of Neurology, Kyoto University School of Medicine, Japan.

Twenty two patients with cervical and axial dystonias were treated with Japanese type A botulinum toxin. Injections were given repeatedly at intervals of 28-30 days to carefully chosen muscles with increased activities, with a maximum dose per session of 300 units. The maximum improvements in subjective and objective ratings were obtained only after repeated injections. No anti-toxin antibodies were detected; nor did any muscle fail to respond to the toxin. During the treatment, previously "silent" muscles were activated to reproduce the original abnormal posture, as if driven by a central motor programme. This resistance to treatment was overcome by injecting the toxin into newly activated muscles. Repeated injections are thus required to override central mechanisms in dystonias or to maximise drug delivery to large muscles. Antibody development may be controlled by the use of a less immunogenic toxin.

© 1994 by Journal of Neurology, Neurosurgery, and Psychiatry



This article has been cited by other articles:


Home page
 NeurologyHome page
A. Brashear, M. F. Lew, D. D. Dykstra, C. L. Comella, S. A. Factor, R. L. Rodnitzky, R. Trosch, C. Singer, M. F. Brin, J. J. Murray, et al.
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
Neurology, October 22, 1999; 53(7): 1439 - 1439.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1994 by the BMJ Publishing Group Ltd.